The objective of this study was a detailed in vivo examination of regional cerebral, including cortical and subcortical, VAChT [18F]-FEOBV (fluoroethoxybenzovesamicol) PET binding expression in Parkinson's disease subjects and correlations with ratings of the four Parkinson's disease cardinal motor features. Here, SLC18A3 is linked to Parkinson disease.